Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

2.1. Patients

YZ Yeye Zhou
XZ Xiaoyi Zhang
HQ Haifeng Qin
ZZ Zixuan Zhao
JL Jihui Li
BZ Bin Zhang
SS Shibiao Sang
YW Yiwei Wu
SD Shengming Deng
ask Ask a question
Favorite

A total of 51 PTCL patients who underwent pre-treatment 18F-FDG PET/CT from March 2013 to May 2019 were enrolled in the present study. Inclusion criteria were set as follows: (1) histopathologically confirmed as PTCL (PTCL-NOS, AITL, or ALCL ALK-) and (2) availability of digital image data for analysis. ALCL ALK+ patients who had superior outcome after CHOP or CHOP-like regimens were excluded.

Characteristics of patients included age, gender, B symptoms, LDH (lactate dehydrogenase) level, IPI score, NCCN-IPI score, prognostic index for T-cell lymphoma (PIT) score, Eastern Cooperative Oncology Group (ECOG) performance status, Ann Arbor stage, bone marrow biopsy, and PET/CT data.

Copyright and License information:  ©2020 Yeye Zhou et al.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A